文献速递免疫规划传染病防控与疫情报告

不同基础免疫程序对mRNA加强针对SARS-CoV-2感染预防效果的比较:基于病毒监测社区队列的时变队列试验模拟分析

Comparative effectiveness of different primary vaccination courses on mRNA-based booster vaccines against SARs-COV-2 infections: a time-varying cohort analysis using trial emulation in the Virus Watch community cohort.
PubMed 文献 · Int J Epidemiol · 2023-01-01

在英格兰和威尔士前瞻性社区队列中,采用试验模拟方法分析19159名已接种mRNA加强针的成人,比较牛津-阿斯利康ChAdOx1与辉瑞-BioNTech BNT162b2基础免疫程序对SARS-CoV-2感染的保护效果。中位随访至2022年1月23日,ChAdOx1基础组感染率7.4%(n=863),BNT162b2基础组7.7%(n=571),汇总调整HR为1.01(95%CI 0.90-1.13)。结论:接种mRNA加强针后,两种基础免疫程序的保护效果无差异。

要点

  • 接种mRNA加强针后,ChAdOx1与BNT162b2基础免疫程序对SARS-CoV-2感染的保护无差异(aHR 1.01,95%CI 0.90-1.13)。
  • 该结果与加强针前研究显示的BNT162b2优于ChAdOx1不同。
  • 研究采用试验模拟方法控制因适应症随时间变化的混杂。

核心结论

  • 接种mRNA加强针后,BNT162b2基础免疫程序与ChAdOx1基础免疫程序对SARS-CoV-2感染的保护效果无差异。
  • 该结果与加强针前研究显示的BNT162b2优于ChAdOx1不同。

研究设计与样本

  • 在英格兰和威尔士开展的前瞻性社区观察性队列研究,采用试验模拟方法。
  • 对8个成人队列结果进行荟萃分析,加强针接种时间在2021年9月16日至2022年1月5日之间错开,随访至2022年1月23日。
  • 共分析19159名参与者,其中ChAdOx1基础免疫程序11709人,BNT162b2基础免疫程序7450人。
  • 使用Cox比例风险模型,调整年龄、性别、少数族裔状态、临床脆弱性和贫困程度。

主要发现

  • 在接种mRNA加强针的成人中,ChAdOx1基础免疫程序组SARS-CoV-2感染率为7.4%(n=863),BNT162b2基础免疫程序组为7.7%(n=571)。
  • 汇总调整风险比(aHR)为1.01,95%置信区间(CI)为0.90至1.13。
  • 中位年龄、临床脆弱状态和感染率随时间波动。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The Omicron B.1.1.529 variant increased severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections in doubly vaccinated individuals, particularly in the Oxford-AstraZeneca COVID-19 vaccine (ChAdOx1) recipients. To tackle infections, the UK's booster vaccination programmes used messenger ribonucleic acid (mRNA) vaccines irrespective of an individual's primary course vaccine type, and prioritized the clinically vulnerable. These mRNA vaccines included the Pfizer-BioNTech COVID-19 vaccine (BNT162b2) the Moderna COVID-19 vaccine (mRNA-1273). There is limited understanding of the effectiveness of different primary vaccination courses on mRNA booster vaccines against SARs-COV-2 infections and how time-varying confounders affect these evaluations. METHODS: Trial emulation was applied to a prospective community observational cohort in England and Wales to reduce time-varying confounding-by-indication driven by prioritizing vaccination based upon age, vulnerability and exposure. Trial emulation was conducted by meta-analysing eight adult cohort results whose booster vaccinations were staggered between 16 September 2021 and 05 January 2022 and followed until 23 January 2022. Time from booster vaccination until SARS-CoV-2 infection, loss of follow-up or end of study was modelled using Cox proportional hazard models and adjusted for age, sex, minority ethnic status, clinically vulnerability and deprivation. RESULTS: A total of 19 159 participants were analysed, with 11 709 ChAdOx1 primary courses and 7450 BNT162b2 primary courses. Median age, clinical vulnerability status and infection rates fluctuate through time. In mRNA-boosted adults, 7.4% (n = 863) of boosted adults with a ChAdOx1 primary course experienced a SARS-CoV-2 infection compared with 7.7% (n = 571) of those who had BNT162b2 as a primary course. The pooled adjusted hazard ratio (aHR) was 1.01 with a 95% confidence interval (CI) of: 0.90 to 1.13. CONCLUSION: After an mRNA booster dose, we found no difference in protection comparing those with a primary course of BNT162b2 with those with a ChAdOx1 primary course. This contrasts with pre-booster findings where previous research shows greater effectiveness of BNT162b2 than ChAdOx1 in preventing infection.

来源:Int J Epidemiol,查看原文。版权归原作者所有。

引用

  1. Nguyen VG, Yavlinsky A, Beale S, et al. Comparative effectiveness of different primary vaccination courses on mRNA-based booster vaccines against SARs-COV-2 infections: a time-varying cohort analysis using trial emulation in the Virus Watch community cohort. Int J Epidemiol. 2023. PMID: 36655537. doi:10.1093/ije/dyad002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。